Innovative Swiss-German R&D firm seeks funding partner for advanced medical cannabis inhalation technology
Highly-specialized, Swiss-German R&D firm first to market with disruptive, advanced medical inhaler for clean cannabis extracts seeks strategic funding partner
Listing ID:
15959335429
Licence(s) Held:
N/A
Seeking strategic equity partner to fund up to ~ €1.5 million for accelerated development
Listing Details:
A German R&D company focused on developing vaporizer technology as a medical device for liquid cannabis extracts aiming to solve the core issues medical inhalation today
The technology excels in precisely evaporating small to high dosages in a single inhalation, ensuring optimal particle size for effective lung delivery
Different dosages will rely on dose specific cartridges, all working on the same inhalation platform technology
The technology is currently patent-pending, with anticipated patent grants in Europe, USA and Australia slated in 2024 or 2025
ISO 13485 certification to be certified in Q2 2024
Experienced, industry-leading international team possessing profound knowledge in medical/pharma R&D, expertise in inhalation technologies, and a strong background in the medical cannabis regulatory field
The company specializes in the development and sale of customized medical inhalers, achieving sustainable profits through strategic licensing agreements with pharmaceutical customers
Company is seeking strategic funding partner for accelerated development and bringing the product to market
15959335429
NEW CANNABIS BUSINESSES FOR SALE
See the latest cannabis business listings on the market including dispensaries, cultivation facilities, greenhouses, labs, and more. If you're looking to invest, acquire, or expand, these business opportunities provide the perfect starting point to grow your footprint in the cannabis industry.
36324927098
Licensed Colombian medical cannabis platform targeting EU pharmaceutical market seeks $3M equity partner
Premium, fully licensed Colombian cannabis cultivation platform offering pharmaceutical-grade production at industry-leading costs, with secured European market access and scalable growth potential
29345918591
State-of-the-art, ~130,000 sq. ft. production facility with 20.5 tonnes annual capacity and & EU-GMP designed processing hub
Opportunity to acquire a custom-designed, ~130,000 sq. ft. turnkey production asset including 84,000 square feet of canopy designed for pharmaceutical-grade output. This unique opportunity allows for a clean-slate acquisition of world-class infrastructure providing an immediate entry point into the global medicinal and premium international markets.